|
|
Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis |
Xin Wu1, Xiaobao Sheng2,3, Rong Sheng1, Hongjuan Lu1, Huji Xu1,4,5() |
1. Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, the Second Military Medical University, Shanghai 200003, China 2. School of Economics and Management, Tongji University, Shanghai 200092, China 3. The Third Research Institute of the Ministry of Public Security, Shanghai 200031, China 4. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 100084, China 5. Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing 100084, China |
|
|
Abstract Although many drugs and therapeutic strategies have been developed for rheumatoid arthritis (RA) treatment, numerous patients with RA fail to respond to currently available agents. In this review, we provide an overview of the complexity of this autoimmune disease by showing the rapidly increasing number of genes associated with RA. We then systematically review various factors that have a predictive value (predictors) for the response to different drugs in RA treatment, especially recent advances. These predictors include but are certainly not limited to genetic variations, clinical factors, and demographic factors. However, no clinical application is currently available. This review also describes the challenges in treating patients with RA and the need for personalized medicine. At the end of this review, we discuss possible strategies to enhance the prediction of drug responsiveness in patients with RA.
|
Keywords
rheumatoid arthritis
gene
clinical markers
therapy
|
Corresponding Author(s):
Huji Xu
|
Just Accepted Date: 20 November 2018
Online First Date: 14 January 2019
Issue Date: 02 August 2019
|
|
1 |
RC Lawrence, DT Felson, CG Helmick, LM Arnold, H Choi, RA Deyo, S Gabriel, R Hirsch, MC Hochberg, GG Hunder, JM Jordan, JN Katz, HM Kremers, F Wolfe; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58(1): 26–35
https://doi.org/10.1002/art.23176
pmid: 18163497
|
2 |
CG Helmick, DT Felson, RC Lawrence, S Gabriel, R Hirsch, CK Kwoh, MH Liang, HM Kremers, MD Mayes, PA Merkel, SR Pillemer, JD Reveille, JH Stone; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58(1): 15–25
https://doi.org/10.1002/art.23177
pmid: 18163481
|
3 |
PC Taylor, M Feldmann. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5(10): 578–582
https://doi.org/10.1038/nrrheum.2009.181
pmid: 19798034
|
4 |
HE Seymour, A Worsley, JM Smith, SH Thomas. Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol 2001; 51(3): 201–208
https://doi.org/10.1046/j.1365-2125.2001.00321.x
pmid: 11298065
|
5 |
JO Costa, LL Lemos, MA Machado, AM Almeida, AM Kakehasi, VE Araújo, ML Cherchiglia, EI Andrade, FA Acurcio. Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Rev Bras Reumatol 2015; 55(2): 146–158
https://doi.org/10.1016/j.rbr.2014.10.009
pmid: 25593074
|
6 |
LJ Scott. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs 2014; 74(12): 1379–1410
https://doi.org/10.1007/s40265-014-0258-9
pmid: 25034360
|
7 |
P Joshi, SS Dhaneshwar. An update on disease modifying antirheumatic drugs. Inflamm Allergy Drug Targets 2014; 13(4): 249–261
https://doi.org/10.2174/187152811304140915152102
pmid: 25244345
|
8 |
A Mitchell, HY Chang, L Daugherty, M Fraser, S Hunter, R Lopez, C McAnulla, C McMenamin, G Nuka, S Pesseat, A Sangrador-Vegas, M Scheremetjew, C Rato, SY Yong, A Bateman, M Punta, TK Attwood, CJ Sigrist, N Redaschi, C Rivoire, I Xenarios, D Kahn, D Guyot, P Bork, I Letunic, J Gough, M Oates, D Haft, H Huang, DA Natale, CH Wu, C Orengo, I Sillitoe, H Mi, PD Thomas, RD Finn. The InterPro protein families database: the classification resource after 15 years. Nucleic Acids Res 2015; 43(Database issue): D213–D221
https://doi.org/10.1093/nar/gku1243
pmid: 25428371
|
9 |
RJ Kinsella, A Kahari, S Haider, J Zamora, G Proctor, G Spudich, J Almeida-King, D Staines, P Derwent, A Kerhornou, P Kersey, P Flicek. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford) 2011; 2011: bar030
https://doi.org/10.1093/database/bar030
|
10 |
H Okamoto, A Kobayashi. Tyrosine kinases in rheumatoid arthritis. J Inflamm (Lond) 2011; 8(1): 21
https://doi.org/10.1186/1476-9255-8-21
pmid: 21861931
|
11 |
A Opar. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 2010; 9(4): 257–258
https://doi.org/10.1038/nrd3155
pmid: 20357793
|
12 |
P Vasanthi, G Nalini, G Rajasekhar. Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review. APLAR J Rheumatol 2007; 10(4): 270–274
https://doi.org/10.1111/j.1479-8077.2007.00305.x
|
13 |
EA Moelants, A Mortier, J Van Damme, P Proost. Regulation of TNF-a with a focus on rheumatoid arthritis. Immunol Cell Biol 2013; 91(6): 393–401
https://doi.org/10.1038/icb.2013.15
pmid: 23628802
|
14 |
D Plant, AG Wilson, A Barton. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 2014; 10(6): 329–337
https://doi.org/10.1038/nrrheum.2014.16
pmid: 24535543
|
15 |
P Barrera, A van der Maas, AE van Ede, BA Kiemeney, RF Laan, LB van de Putte, PL van Riel. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-a antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford) 2002; 41(4): 430–439
https://doi.org/10.1093/rheumatology/41.4.430
pmid: 11961174
|
16 |
B Saleem, H Keen, V Goeb, R Parmar, S Nizam, EM Hensor, SM Churchman, M Quinn, R Wakefield, PG Conaghan, F Ponchel, P Emery. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69(9): 1636–1642
https://doi.org/10.1136/ard.2009.117341
pmid: 20421345
|
17 |
P Bohanec Grabar, B Rozman, M Tomsic, D Suput, D Logar, V Dolzan. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64(9): 871–876
https://doi.org/10.1007/s00228-008-0498-2
pmid: 18496682
|
18 |
P Bohanec Grabar, I Grabnar, B Rozman, D Logar, M Tomsic, D Suput, T Trdan, L Peterlin Masic, A Mrhar, V Dolzan. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009; 37(10): 2061–2068
https://doi.org/10.1124/dmd.109.027482
pmid: 19581389
|
19 |
JD Cañete, B Suárez, MV Hernández, R Sanmartí, I Rego, R Celis, C Moll, JA Pinto, FJ Blanco, F Lozano. Influence of variants of Fcγ receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor α therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68(10): 1547–1552
https://doi.org/10.1136/ard.2008.096982
pmid: 18930989
|
20 |
MJ Morales-Lara, P Conesa-Zamora, MS García-Simón, F Pedrero, V Santaclara, M Perez-Guillermo, E Soriano-Navarro. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol 2010; 39(6): 518–520
https://doi.org/10.3109/03009741003781969
pmid: 20560817
|
21 |
R Rizzo, M Rubini, M Govoni, M Padovan, L Melchiorri, M Stignani, S Carturan, S Ferretti, F Trotta, OR Baricordi. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics 2006; 16(9): 615–623
https://doi.org/10.1097/01.fpc.0000230115.41828.3a
pmid: 16906016
|
22 |
OR Baricordi, M Govoni, R Rizzo, F Trotta. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment. Ann Rheum Dis 2007; 66(8): 1125–1126
https://doi.org/10.1136/ard.2006.064022
pmid: 17626975
|
23 |
LK Stamp, JL O’Donnell, PT Chapman, ML Barclay, MA Kennedy, CM Frampton, RL Roberts. Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann Rheum Dis 2009; 68(1): 154–155
https://doi.org/10.1136/ard.2008.089383
pmid: 19088262
|
24 |
M Fabris, L Quartuccio, S Lombardi, M Saracco, F Atzeni, A Carletto, M Cimmino, C Fabro, E Pontarini, R Pellerito, LM Bambara, P Sarzi-Puttini, M Cutolo, M Manfredi, M Benucci, P Morassi, F Fischetti, M Padovan, M Govoni, F Curcio, E Tonutti, S De Vita. The CC homozygosis of the −174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2012; 11(5): 315–320
https://doi.org/10.1016/j.autrev.2010.06.012
pmid: 20974296
|
25 |
H Schotte, B Schlüter, S Drynda, P Willeke, N Tidow, G Assmann, W Domschke, J Kekow, M Gaubitz. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64(4): 575–581
https://doi.org/10.1136/ard.2004.027672
pmid: 15345504
|
26 |
LB Hughes, TM Beasley, H Patel, HK Tiwari, SL Morgan, JE Baggott, KG Saag, J McNicholl, LW Moreland, GS Alarcón, SL Jr Bridges. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006; 65(9): 1213–1218
https://doi.org/10.1136/ard.2005.046797
pmid: 16439441
|
27 |
SK Kim, JB Jun, A El-Sohemy, SC Bae. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 2006; 33(7): 1266–1274
pmid: 16758511
|
28 |
R Cáliz, J del Amo, A Balsa, F Blanco, L Silva, R Sanmarti, FG Martínez, MD Collado, MC Ramirez, D Tejedor, M Artieda, D Pascual-Salcedo, N Oreiro, JL Andreu, E Graell, L Simon, A Martínez, J Mulero. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol 2012; 41(1): 10–14
https://doi.org/10.3109/03009742.2011.617312
pmid: 22044028
|
29 |
S Inoue, M Hashiguchi, K Takagi, S Kawai, M Mochizuki. Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. Yakugaku Zasshi 2009; 129(7): 843–849
https://doi.org/10.1248/yakushi.129.843
pmid: 19571519
|
30 |
R Takatori, KA Takahashi, D Tokunaga, T Hojo, M Fujioka, T Asano, T Hirata, Y Kawahito, Y Satomi, H Nishino, T Tanaka, Y Hirota, T Kubo. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24(5): 546–554
pmid: 17181924
|
31 |
M Cuchacovich, L Soto, M Edwardes, M Gutierrez, C Llanos, D Pacheco, F Sabugo, M Alamo, C Fuentealba, L Villanueva, H Gatica, I Schiattino, L Salazaro, D Catalan, O Valenzuela, F Salazar-Onfray, JC Aguillón. Tumour necrosis factor (TNF)α –308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35(6): 435–440
https://doi.org/10.1080/03009740600904284
pmid: 17343250
|
32 |
S Stojanović, T Jevtović-Stoimenov, A Stanković, D Pavlović, J Neković, B Stamenković, A Dimić, M Marinković. Association of TNF-α polymorphism (−308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept. Srp Arh Celok Lek 2011; 139(11-12): 784–789 (in Serbian)
https://doi.org/10.2298/SARH1112784S
pmid: 22338476
|
33 |
M Fabris, E Di Poi, S Sacco, G Damante, L Sinigaglia, G Ferraccioli. TNF-α gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-α agents: preliminary results. Reumatismo 2002; 54(1): 19–26 (in Italian)
pmid: 12089610
|
34 |
YH Lee, JD Ji, SC Bae, GG Song. Associations between tumor necrosis factor-α (TNF-α) –308 and –238 G/A polymorphisms and shared epitope status and responsiveness to TNF-α blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 2010; 37(4): 740–746
https://doi.org/10.3899/jrheum.090707
pmid: 20194454
|
35 |
C Rooryck, T Barnetche, C Richez, A Laleye, B Arveiler, T Schaeverbeke. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008; 26(2): 340–342
pmid: 18565259
|
36 |
CM Ulrich, Y Yasui, R Storb, MM Schubert, JL Wagner, J Bigler, KS Ariail, CL Keener, S Li, H Liu, FM Farin, JD Potter. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98(1): 231–234
https://doi.org/10.1182/blood.V98.1.231
pmid: 11418485
|
37 |
PB Grabar, B Rozman, D Logar, S Praprotnik, V Dolzan. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68(8): 1367–1368
https://doi.org/10.1136/ard.2008.099093
pmid: 19605743
|
38 |
E Rath, J Zwerina, B Oppl, V Nell-Duxneuner. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 2015; 165(1-2): 28–35
https://doi.org/10.1007/s10354-014-0331-8
pmid: 25676699
|
39 |
PC Taylor, RO Williams. Combination cytokine blockade: the way forward in therapy for rheumatoid arthritis? Arthritis Rheumatol 2015; 67(1): 14–16
https://doi.org/10.1002/art.38893
pmid: 25302944
|
40 |
LG van Baarsen, CA Wijbrandts, F Rustenburg, T Cantaert, TC van der Pouw Kraan, DL Baeten, BA Dijkmans, PP Tak, CL Verweij. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010; 12(1): R11
https://doi.org/10.1186/ar2912
pmid: 20096109
|
41 |
TD de Jong, S Vosslamber, M Blits, G Wolbink, MT Nurmohamed, CJ van der Laken, G Jansen, AE Voskuyl, CL Verweij. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther 2015; 17(1): 78
https://doi.org/10.1186/s13075-015-0564-y
pmid: 25889713
|
42 |
J Rodríguez-Carrio, P López, A Suárez. Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. Clin Sci (Lond) 2015; 128(8): 449–464
https://doi.org/10.1042/CS20140554
pmid: 25630235
|
43 |
M Jani, H Chinoy, RB Warren. Em Griffiths C, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich KL, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 2015; 385(8): S48
|
44 |
T Takeuchi, K Yamamoto, H Yamanaka, N Ishiguro, Y Tanaka, K Eguchi, A Watanabe, H Origasa, T Shoji, N Miyasaka, T Koike. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod Rheumatol 2015; 25(1): 11–20
https://doi.org/10.3109/14397595.2014.904475
pmid: 24842476
|
45 |
S Blaschke, K Rinke, M Maring, T Flad, S Patschan, O Jahn, CA Mueller, GA Mueller, H Dihazi. Haptoglobin-a1, -a2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis. Arthritis Res Ther 2015; 17(1): 45
https://doi.org/10.1186/s13075-015-0553-1
pmid: 25884688
|
46 |
F Atzeni, S Bongiovanni, A Marchesoni, M Filippini, R Caporali, R Gorla, L Cavagna, EG Favalli, F Saccardo, P Sarzi-Puttini. Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine 2014; 81(1): 37–40
https://doi.org/10.1016/j.jbspin.2013.04.005
pmid: 23731638
|
47 |
C Barnabe, J Homik, SG Barr, L Martin, WP Maksymowych. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol 2014; 41(8): 1607–1613
https://doi.org/10.3899/jrheum.131451
pmid: 25028371
|
48 |
LE Kristensen, MC Kapetanovic, A Gülfe, M Söderlin, T Saxne, P Geborek. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47(4): 495–499
https://doi.org/10.1093/rheumatology/ken002
pmid: 18316338
|
49 |
S Luban, ZG Li. Citrullinated peptide and its relevance to rheumatoid arthritis: an update. Int J Rheum Dis 2010; 13(4): 284–287
https://doi.org/10.1111/j.1756-185X.2010.01553.x
pmid: 21199462
|
50 |
D Pietrapertosa, B Tolusso, E Gremese, MC Papalia, SL Bosello, G Peluso, L Petricca, A Michelutti, F Faustini, AL Fedele, G Ferraccioli. Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. Clin Chem Lab Med 2010; 48(6): 829–834
https://doi.org/10.1515/CCLM.2010.152
pmid: 20298138
|
51 |
J Narváez, C Díaz-Torné, JM Ruiz, MV Hernandez, V Torrente-Segarra, S Ros, A Rodriguez de la Serna, C Díaz-López, R Sanmartí, JM Nolla. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 2011; 29(6): 991–997
pmid: 22133052
|
52 |
L Chara, A Sánchez-Atrio, A Pérez, E Cuende, F Albarrán, A Turrión, J Chevarria, AA del Barco, MA Sánchez, J Monserrat, A Prieto, A de la Hera, I Sanz, D Diaz, M Alvarez-Mon. The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis. J Transl Med 2015; 13(1): 2
https://doi.org/10.1186/s12967-014-0375-y
pmid: 25592233
|
53 |
G Jutley, K Raza, CD Buckley. New pathogenic insights into rheumatoid arthritis. Curr Opin Rheumatol 2015; 27(3): 249–255
https://doi.org/10.1097/BOR.0000000000000174
pmid: 25775189
|
54 |
A Johannsen, C Susin, A Gustafsson. Smoking and inflammation: evidence for a synergistic role in chronic disease. Periodontol 2000 2014; 64(1): 111–126
https://doi.org/10.1111/j.1600-0757.2012.00456.x
pmid: 24320959
|
55 |
IC Scott, R Tan, D Stahl, S Steer, CM Lewis, AP Cope. The protective effect of alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(5): 856–867
https://doi.org/10.1093/rheumatology/kes376
pmid: 23287363
|
56 |
KL Hyrich, KD Watson, AJ Silman, DP Symmons; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNFα therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45(12): 1558–1565
https://doi.org/10.1093/rheumatology/kel149
pmid: 16705046
|
57 |
C Lin, EW Karlson, H Canhao, TA Miller, D Dligach, PJ Chen, RN Perez, Y Shen, ME Weinblatt, NA Shadick, RM Plenge, GK Savova. Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records. PLoS One 2013; 8(8): e69932
https://doi.org/10.1371/journal.pone.0069932
pmid: 23976944
|
58 |
SK Sieberts, F Zhu, J García-García, E Stahl, A Pratap, G Pandey, D Pappas, D Aguilar, B Anton, J Bonet, R Eksi, O Fornés, E Guney, H Li, MA Marín, B Panwar, J Planas-Iglesias, D Poglayen, J Cui, AO Falcao, C Suver, B Hoff, VS Balagurusamy, D Dillenberger, EC Neto, T Norman, T Aittokallio, M Ammad-Ud-Din, CA Azencott, V Bellón, V Boeva, K Bunte, H Chheda, L Cheng, J Corander, M Dumontier, A Goldenberg, P Gopalacharyulu, M Hajiloo, D Hidru, A Jaiswal, S Kaski, B Khalfaoui, SA Khan, ER Kramer, P Marttinen, AM Mezlini, B Molparia, M Pirinen, J Saarela, M Samwald, V Stoven, H Tang, J Tang, A Torkamani, JP Vert, B Wang, T Wang, K Wennerberg, NE Wineinger, G Xiao, Y Xie, R Yeung, X Zhan, C; Members of the Rheumatoid Arthritis Challenge Consortium, Greenberg J Zhao, J Greenberg, J Kremer, K Michaud, A Barton, M Coenen, X Mariette, C Miceli, N Shadick, M Weinblatt, N de Vries, PP Tak, D Gerlag, TW Huizinga, F Kurreeman, CF Allaart, S Louis Bridges Jr, L Criswell, L Moreland, L Klareskog, S Saevarsdottir, L Padyukov, PK Gregersen, S Friend, R Plenge, G Stolovitzky, B Oliva, Y Guan, LM Mangravite, SL Bridges, L Criswell, L Moreland, L Klareskog, S Saevarsdottir, L Padyukov, PK Gregersen, S Friend, R Plenge, G Stolovitzky, B Oliva, Y Guan, LM Mangravite. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun 2016; 7: 12460
https://doi.org/10.1038/ncomms12460
pmid: 27549343
|
59 |
S Viatte, D Plant, B Han, B Fu, A Yarwood, W Thomson, DP Symmons, J Worthington, A Young, KL Hyrich, AW Morgan, AG Wilson, JD Isaacs, S Raychaudhuri, A Barton. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA 2015; 313(16): 1645–1656
https://doi.org/10.1001/jama.2015.3435
pmid: 25919528
|
60 |
T Takeuchi, N Miyasaka, Y Tatsuki, T Yano, T Yoshinari, T Abe, T Koike. Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis 2012; 71(9): 1583–1585
https://doi.org/10.1136/annrheumdis-2011-201069
pmid: 22562980
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|